Cure­Vac nabs a top No­var­tis sci­en­tist for CSO slot as mR­NA vac­cines seize the spot­light

One of the key play­ers in the race to de­vel­op a new mR­NA vac­cine to fight Covid-19 has reshuf­fled the top spots in the ex­ec­u­tive suite. And they’re bring­ing in a No­var­tis vet out of Har­vard to spear­head their work on mR­NA.

Cure­Vac, which just filed for an IPO that’s still tak­ing shape, has for­mal­ly hand­ed Franz-Wern­er Haas the CEO ti­tle, af­ter giv­ing it to him on an in­ter­im ba­sis. And the still rather stealthy Ger­man biotech large­ly owned by bil­lion­aire Di­et­mar Hopp has re­cruit­ed Ig­or Splaws­ki as its chief sci­en­tif­ic of­fi­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER